Panels für die Diagnostik
Panels für die Diagnostik
Wählen Sie Ihr Panel, entweder direkt ab Lager geliefert oder individuell auf Anfrage angepasst:
Inhibitionspanels, Interferenzpanels, abgestimmte Sets, Q.C.-Panels (Qualitätskontrollpanels), Serokonversionspanels und Standardisierungspanels.
Seroconversion-Panels
Unsere Seroconversion-Panels (SCPs) wurden aus unverarbeitetem Plasma entwickelt. Dies geschah durch die Gewinnung von Plasma eines Individuums während der Entwicklung einer Infektion und der daraus resultierenden immunologischen Reaktion. Unsere Seroconversion-Panels enthalten definierte Infektionsmarker und umfassen umfassende Probendaten für vergleichende Analysen.
Unsere SCPs sind für den Einsatz in Standardtests durch Diagnostikhersteller und Forschende während der Assay-Entwicklung, Evaluierung, Fehlersuche und Nachbeobachtung von IgM-/IgG-Antikörper-Testsystemen und -methoden vorgesehen. Darüber hinaus dienen diese Panels als Validierungswerkzeug zur Bestimmung der diagnostischen Sensitivität, zur Messung der analytischen Sensitivität, zur Identifizierung von Cut-off-Werten oder zur Untersuchung der humoralen Immunantwort auf eine spezifische Infektion.
Hier finden Sie eine vielfältige Auswahl an Produkten mit hochwertigen Datensätzen, die Ihnen bei der Evaluierung Ihrer Assays helfen:
| Order no. | Old profile diagnostics no. | Marker | Panel member | Member volumes | Time period for donation | |
|---|---|---|---|---|---|---|
| SCP-CMV-001 | RP-003 | CMV | 15 | 0.5 mL | Mar 94 – Jul 94 |  |
| SCP-CMV-002 | RP-019 | CMV | 25 | 0.5 mL | Feb 99 - May 99 | |
| SCP-CMV-005 | CMV | 6 | 0.5 mL | Nov 10 – Dec 10 | |
|
| SCP-CMV-006 | CMV | 24 | 0.5 mL | Feb 11 – Jun 11 | |
|
| SCP-CMV-007 | CMV | 20 | 0.5 mL | Apr 12 – Aug 12 | |
|
| SCP-EBV-001 | EBV | 27 | 0.5 mL | Oct 12 – Feb 13 | |
|
| SCP-EBV-002 | EBV | 25 | 0.5 mL | Apr 13 - Nov 13 | |
|
| SCP-HAV-001 | RP-004 | HAV | 15 | 0.3 mL | Sep 94 – Nov 94 | |
| SCP-HAV-002 | RP-013 | HAV | 15 | 0.3 mL | Apr 96 – Oct 96 | |
| SCP-HBV-001 | RP-009 | HBV | 20 | 0.5 mL | Jul 95 – Feb 96 | |
| SCP-HBV-002 | RP-016 | HBV | 20 | 0.5 mL | Jul 96 – Dec 96 | |
| SCP-HBV-003 | RP-028 | HBV | 9 | 0.5 mL | Oct 96 – Nov 96 | |
| SCP-HBV-004 | RP-017 | HBV | 30 | 0.5 mL | Jan 97 – Jul 97 | |
| SCP-HBV-005 | RP-027 | HBV | 7 | 0.5 mL | Nov 97 – Jan 98 | |
| SCP-HBV-006 | RP-037 | HBV | 4 | 0.5 mL | Sep 98 | |
| SCP-HBV-007 | RP-020 | HBV | 3 | 0.5 mL | Jan 99 - Feb 99 | |
| SCP-HCV-001 | RP-006 | HCV | 20 | 0.5 mL | Jul 90 – Dec 91 | |
| SCP-HCV(Ag)-003 | HCV Ag only | 5 | 1.0 mL | Sep 13 - Oct 13 | |
|
| SCP-HCV-004 | HCV | 5 | 1.0 mL | Aug 12 - Sep 12 | |
|
| SCP-HCV(Ag)-005 | HCV Ag only | 7 | 1.0 mL | Jul 12 - Aug 12 | |
|
| SCP-HCV(Ag)-006 | HCV Ag only | 6 | 1.0 mL | Jan 14 | |
|
| SCP-HCV(Ag)-007 | HCV Ag only | 18 | 1.0 mL | Jul 12 - Nov 12 | |
|
| SCP-HCV(Ag)-008 | HCV Ag only | 11 | 1.0 mL | Dec 12 - Jan 13 | |
|
| SCP-HCV-009 | RP-038 | HCV | 8 | 0.5 mL | Oct 00 – Dec 00 | |
| SCP-HCV-010 | HCV | 9 | 1.0 mL | Feb 12 - Mar 12 | |
|
| SCP-HCV-011 | HCV | 5 | 1.0 mL | Mar 12 - Apr 12 | |
|
| SCP-HCV-012 | HCV | 4 | 1.0 mL | Oct 13 | |
|
| SCP-HEV-001a | HEV | 8 | 1.0 mL | Jun 11 – Aug 11 | |
|
| SCP-HEV-001b | HEV | 8 | 1.5 mL | Jun 11 – Aug 11 | |
|
| SCP-HEV-002a | HEV | 8 | 1.0 mL | Jun 11 – Sep 11 | |
|
| SCP-HEV-003a | HEV | 12 | 1.0 mL | Jun 11 – Oct 11 | |
|
| SCP-HEV-003b | HEV | 12 | 1.5 mL | Jun 11 – Oct 11 | |
|
| SCP-HEV-004a | HEV | 11 | 1.0 mL | Aug 11 – Sep 11 | |
|
| SCP-HEV-004b | HEV | 11 | 1.5 mL | Aug 11 – Sep 11 | |
|
| SCP-HEV-005a | HEV | 20 | 1.0 mL | Jul 11 – Dec 11 | |
|
| SCP-HEV-005b | HEV | 20 | 1.5 mL | Jul 11 – Dec 11 | |
|
| SCP-HEV-006a | HEV | 23 | 1.0 mL | Jul 11 – Jan 12 | |
|
| SCP-HEV-006b | HEV | 23 | 1.5 mL | Jul 11 – Jan 12 | |
|
| SCP-HEV-007a | HEV | 17 | 1.0 mL | Aug 11 – Jan 12 | |
|
| SCP-HEV-008a | HEV | 11 | 1.0 mL | Aug 11 – Dec 11 | |
|
| SCP-HEV-008b | HEV | 11 | 1.5 mL | Aug 11 – Dec 11 | |
|
| SCP-HEV-009a | HEV | 9 | 1.0 mL | Aug 11 – Dec 11 | |
|
| SCP-HEV-009b | HEV | 9 | 1.5 mL | Aug 11 – Dec 11 | |
|
| SCP-HIV1-002 | RP-002 | HIV 1 | 20 | 1.0 mL | May 88 – Sep 88 | |
| SCP-HIV1-003 | RP-007 | HIV 1 | 7 | 1.0 mL | Apr 94 - Jun 94 | |
| SCP-HIV1-004 | RP-034 | HIV 1 | 7 | 1.0 mL | Apr 97 - Jun 97 | |
| SCP-HIV1-005 | RP-018 | HIV 1 | 25 | 1.0 mL | Jan 98 - Jun 98 | |
| SCP-HIV1-006 | RP-029 | HIV 1 | 17 | 1.0 mL | Feb 99 - May 99 | |
| SCP-HIV1-007 | RP-033 | HIV 1 | 9 | 1.0 mL | May 00 - Jun 00 | |
| SCP-HIV1-008 | HIV 1 subtype C | 8 | 1.0 mL | Aug 11 - Oct 11 | |
|
| SCP-MEA-001 | RP-005 | Rubeola | 15 | 0.5 mL | May 94 - Jul 94 | |
| SCP-RUB-001 | RP-001 | Rubella | 15 | 1.0 mL | Dec 92 - Jan 93 | |
| SCP-RUB-002 | RP-014 | Rubella | 13 | 1.0 mL | Apr 93 - May 93 | |
| SCP-RUB-003 | RP-011 | Rubella | 20 | 1.0 mL | Mar 96 - Jun 96 | |
| SCP-RUB-004 | Rubella | 15 | 0.5 mL | Mar 15 - May 15 | |
|
| SCP-PARVO-001 | Parvo B19 | 21 | 0.2 mL | |
||
| SCP-TP-001 | Treponema Pallidum (Syphilis) | 30 | 0.5 mL | Jan 24 – Jun 24 | |
|
| SCP-YF-001 | Yellow Fever | 20 | 1.0 mL | Mar 22- Jun 22 | |
|
| SCP-YF-002 | Yellow Fever | 20 | 1.0 mL | Dec 21 - Feb 22 | |
|
| SCP-YF-004 | Yellow Fever | 19 | 1.0 mL | Apr 22 - Jun 22 | |
|
| SCP-YF-005 | Yellow Fever | 20 | 1.0 mL | Dec 21 - Feb 22 | |
|
| SCP-YF-006 | Yellow Fever | 20 | 1.0 mL | Dec 21 - Feb 22 | |
|
| SCP-YF-007 | Yellow Fever | 20 | 1.0 mL | Feb 22 - May 22 | |
|
| SCP-YF-008 | Yellow Fever | 20 | 1.0 mL | Jan 22 - Mar 22 | |
|
| SCP-YF-009 | Yellow Fever | 21 | 1.0 mL | Dec 21 - Feb 22 | |
|
| SCP-YF-010 | Yellow Fever | 20 | 1.0 mL | Jan 22 - Apr 22 | |
Matched Sets
Matched Sets werden genutzt, um potenzielle Einflussfaktoren verschiedener Antikoagulanzien auf Testergebnisse aufzudecken. Erhältlich sind diese Sets von gesunden Spendern in Panels von 5 oder 10 Proben. Gerne stellen wir auf Kundenwunsch auch individuell angepasste Matched Sets bereit. Alle Spender werden mittels CE-zertifizierter Tests negativ/nicht-reaktiv auf Anti-HIV, Anti-HCV und HBsAg getestet.
Selbstverständlich führen wir auch Studien zur Stabilität der Probenlagerung für Sie durch – nutzen Sie unseren Service für Ihr Projekt.
| Order no. | Product description | Volumes |
|---|---|---|
| MSS-005 (5 sample sets) MSS-010 (10 sample sets) or MSS-XXX (customized) | Matched sets small Serum Sodium citrate K2EDTA Lithium heparin | 1.0 mL |
| MSS-005 (5 sample sets) MSS-010 (10 sample sets) or MSS-XXX (customized) | Matched sets large* Serum Sodium citrate K2EDTA K3EDTA Sodium heparin Lithium heparin ACD-B CPDA K-oxalate / Na-fluoride | 1.0 mL |
* oder im Rahmen der Auftragsherstellung
CS-Screening-Test-Panels
CS-Panels werden verwendet, um die Anforderungen gemäß der Verordnung (EU) 2017/746 (IVDR) zu erfüllen, die in den gemeinsamen Spezifikationen (CS) für Klasse-D-Geräte festgelegt sind.
Seroconversionspanels beginnen mit einer oder mehreren negativen Proben und zeichnen sich durch enge Sammlungsintervalle aus.
Wenn Sie weitere Fragen zur IVDR haben oder Unterstützung bei der Umsetzung der Anforderungen benötigen, kontaktieren Sie uns gerne.
Diagnostische Sensitivitätspanels
| Order. no. | Panel | Product description | |
|---|---|---|---|
| Panels for screening tests (acc. to Table 1, CTS): | |||
| CTS-HIV | Anti-HIV 1/2 panel | 400 Anti-HIV 1 positive samples with • 40 non-B-subtypes (in each case at least 3 samples of the subtypes A, C, D, F, G, H, J, K, CRF01_AE, CRF02_AG, CRF06_cpx3, CRF11_cpx and group O) • 3 subtypes B • 357 Anti-HIV 1 samples unspecified 100 Anti-HIV 2 samples | |
| CTS-HIV | 30 HIV seroconversion panels | All seroconversion samples include established positives (they are p24 antigen and/or HIV RNA positive, established/detected by antibody screening (verification) tests and determined to be positive or undetermined by means of confirmatory tests), and include at least 40 early HIV seroconversion samples (these are p24 antigen and/or HIV RNA positive, not established/determined by antibody screening tests and determined as undetermined or negative using confirmatory tests) | |
| CTS-HCV | Anti-HCV panel | 400 Anti-HCV positive samples with • 21 of genotype 1 • 21 of genotype 2 • 21 of genotype 3 • 21 of genotype 4 • 21 of genotype 4 not subtype A • 5 of genotype 5 • 280 HCV samples unspecified | |
| CTS-HCV | 30 HCV seroconversion panels | ||
| CTS-HBsAg | HBsAg Panel | 400 HBsAg positive samples with the different subtypes A1, A2, B1, B2, C1, C2, D1-7, E, F1-4, G, H | |
| CTS-HBsAg | 30 HBV seroconversion panels | ||
Diagnostische Spezifitätspanels
| Order no. | Panels | Product description | |
|---|---|---|---|
| CTS-BDP | Blood donor panels | 5000 (screening test) or 1000 (rapid test) samples from unselected blood donors from at least 2 different European donation centers | |
| CTS-HPP | Hospitalized patient panels | 200 samples from patients suffering from severe illness and on medication | |
| Cross-reaction panels More than 100 samples containing cross-reacting substances such as RF +, autoimmune antibodies, EBV, CMV, hepatitis samples, etc. | |||
| General test panels | RF +, HAMA, pregnant women, multipara, hyper-IgM, hyper-IgG, dialysis patients, influenza vaccinated individuals, etc. 30 samples (in each case 3 samples) | ||
| Blood bank marker panels | Anti-HIV 1, Anti-HCV, HBsAg, Anti-Syphilis etc. 15 samples (in each case 3 samples) | ||
| Herpes panels | Anti-HSV 1, Anti-HSV 2, Anti-VZV, Anti-EBV, Anti-CMV 15 samples (in each case 3 samples) | ||
| Hepatitis panels | Anti-HAV, Anti-HBs, Anti-HBc, Anti-HEV 12 samples (in each case 3 samples) | ||
| Inhibition panels | Hemolytic, lipemic and icteric samples, low, mid and high concentration in addition to a negative control 36 samples (in each case 3 samples) | ||
| Serum / plasma equivalence panels In the case of products intended by the manufacturer for testing serum and plasma, the serum-plasma equivalence must be confirmed in the performance evaluation. Evidence must be provided from at least 50 donations (25 positive and 25 negative). | |||
| 25 negative matched sets | Serum, plasma (including all anticoagulants that might be used) | ||
CS NAT Panels
CS-Panels werden eingesetzt, um die Anforderungen gemäß der Verordnung (EU) 2017/746 (IVDR) zu erfüllen, wie sie in den Gemeinsamen Spezifikationen (CS) für Klasse-D-Produkte festgelegt sind.
Wenn Sie Fragen zur IVDR haben oder Unterstützung bei der Umsetzung der Anforderungen benötigen, stehen wir Ihnen gerne zur Verfügung.
Diagnostische Sensitivitätspanels
| Order no. | Panels | Product description |
|---|---|---|
| Panel for NAT testing (according to Table 2 CS): Panel for Genotype/Subtype Detection/Quantification Efficiency |
||
| NAT-HIV | NAT-HIV 1 Panel | 10 samples of each subtype |
| NAT-HCV | NAT-HCV Panel | 10 samples of each genotype |
| NAT-HBV | NAT-HBV Panel | 10 samples of each subtype |
| Seroconversion panel | ||
| For qualitative PCR tests, diagnostic sensitivity must be evaluated on at least 10 seroconversion panels. They start with (a) negative collection(s) and have narrow collection intervals. |
||
| 10 HIV Seroconversion panel | ||
| 10 HCV Seroconversion panel | ||
| 10 HBV Seroconversion panel | ||
Diagnostische Spezifitätspanels
| Order no. | Panels | Product description |
|---|---|---|
| NAT-BDP | Blood donor panel | 500 samples of unselected blood donors (from at least 2 different European donation centers) for qualitative testing or 100 samples of unselected blood donors for quantitative testing. |
| NAT-HPP | Hospital-patients panel | 200 samples from patients suffering from severe diseases and under medication. |
| Cross contamination panel To investigate possible carryover, at least five test series with alternating high positive and negative samples during robustness testing. The high positive samples contain samples with high viral load. |
||
| CCP-HIV | NAT-HIV Kreuzkontaminationspanel | 5 HIV samples with high titer and 5 negative samples |
| CCP-HCV | NAT-HCV Kreuzkontaminationspanel | 5 HCV samples with high titer and 5 negative samples |
| CCP-HBV | NAT-HBV Kreuzkontaminationspanel | 5 HBV samples with high titer and 5 negative samples |
| Cross-Reactivity Panel By demonstrating an appropriate test design (e.g., sequence comparison) and/or testing on at least 10 specimens, Positive for human samples with related viral infection. |
||
| CRP-HIV | NAT-HIV Cross-Reactivity Panel | 10 human retrovirus positive samples (e.g. HTLV) |
| CRP-HCV | NAT-HCV Cross-Reactivity Panel | 10 human flavivirus positive samples (e.g. HGV, YFV). |
| CRP-HBV | NAT-HBV Cross-Reactivity Panel | 10 human DNA virus positive samples |
| Serum Plasma Equivalent Panel For devices intended by the manufacturer to be tested in serum and plasma, serum-to-plasma correspondence must be demonstrated in the performance evaluation. Evidence must be provided on at least 50 donations (25 positive and 25 negative). |
||
| 25 negative Matched Sets | Serum, plasma (including any anticoagulants that may be used). | |
Inhibitions-Panels
Die Inhibitions-Panels mit hämolytischen, lipämischen und ikterischen Proben dienen der Identifizierung von Inhibitionseffekten in diagnostischen Assays, die durch störende Substanzen entstehen können, wie sie häufig in Serum-, Plasma- oder Vollblutproben vorkommen.
Erhältlich in verschiedenen Kit-Größen: 5, 10 oder mehr Proben von gesunden, normal-spendenden Individuen. Wir bieten auch maßgeschneiderte Lösungen, die exakt auf Ihre Anforderungen abgestimmt sind.
| Order no. | Components (matrix: EDTA) | Concentration range | Quantity | |
|---|---|---|---|---|
| IHH-005 (5 sample sets) IHH-010 (10 sample sets) or IHH-XXX (customized) | Hemolytic negative control Hemolytic plasma low* Hemolytic plasma medium* Hemolytic plasma high* | 0.0 - 0.1 mg/dL 0.5 - 0.7 mg/dL 0.9 - 1.1 mg/dL 1.9 - 2.2 mg/dL | 1.0 mL | |
| Components (matrix: CPD) | ||||
| IHL-005 (5 sample sets) IHL-010 (10 sample sets) or IHL-XXX (customized) | Lipaemic negative control Lipaemic plasma low* Lipaemic plasma medium* Lipaemic plasma high* | 50 - 199.9 mg/dL 200 - 399.9 mg/dL 400 - 800 mg/dL 400 - 800 mg/dL | 1.0 mL | |
| Components (matrix: Serum) | ||||
| IHI-005 (5 sample sets) IHI-010 (10 sample sets) or IHI-XXX (customized) | Icteric negative control** Icteric plasma low** Icteric plasma medium** Icteric plasma high** | to be defined 18 - 22 mg/dL 38 - 42 mg/dL 58 - 62 mg/dL | 1.0 mL | |
| * native samples ** spiked samples |
Interferenz-Panels
Unsere Kreuzreaktions-Panels ermöglichen die gezielte Auswahl spezifischer Kombinationen aus verschiedenen potenziellen Kreuzreaktanten.
Die Panels sind in unterschiedlichen Verpackungsgrößen erhältlich: für ein (ABC-001), fünf (ABC-005) oder zehn (ABC-010) Proben-Sets von gesunden Spendern. Auf Wunsch können wir auch größere Verpackungseinheiten (ABC-XXX) anbieten.
Wir fertigen individuell angepasste Lösungen für Ihre Anforderungen.
| Order no. | Product | Volumes |
|---|---|---|
| BTP-001 BTP-005 BTP-010 or BTP-XXX | General test panels • Rheumatoid factor • HAMA • Pregnant woman • Multipara • Hyper IgM, IgG • Dialysis patient • Recipient of an influenza vaccination (max. 6 months old) | 1.0 mL |
| BBX-001 BBX-005 BBX-010 or BBX-XXX | Blood bank marker panels (3-pack, 6-pack, or made-to-order) • Anti-HIV 1 • Anti-HAV • Anti-HBs • Anti-HTLV I/II • Anti-HCV • Anti-Syphilis • Anti-HBc • HBsAg • Anti-CMV • Anti-Chagas … and more* | 1.0 mL |
| HHV-001 HHV-005 HHV-010 or HHV-XXX | Herpes panels • Anti-HSV 1 • Anti-HSV 2 • Anti-VZV • Anti-EBV • Anti-CMV • Anti-HHV 6 • Anti-HHV 7 • Anti-HHV 8 | 1.0 mL |
| HEPP-001 HEPP-005 HEPP-010 or HEP-XXX | Hepatitis panels • Anti-HAV • HBsAg • Anti-HBs • Anti-HBc • Anti-HCV • Anti-HEV | 1.0 mL |
| NPP-001 NPP-005 NPP-010 or NPP-XXX | Negative plasma panels Can be used to check the specificity of tests • Anti-HIV • Anti-HBs/HBsAg • Anti-HCV • Anti-CMV • Anti-HTLV I/II • Anti-Syphilis … and more* According to the regulatory requirements up to 5000 individuals | 1.0 mL |
| * or contract production | ||
Verschiedene Panels
BIOMEX bietet eine breite Auswahl an weiteren Panels an. Sollten Sie ein spezifisches Panel benötigen, das hier nicht aufgeführt ist, kontaktieren Sie uns gerne. Wir sind in der Lage, individuell angepasste Panels nach Ihren Anforderungen herzustellen.
QC Release Panels
QC-Release-Panels (Serum und Plasma)
Über unsere Spenderzentren und in Kooperation mit Laboratorien stellt BIOMEX nahezu alle Parameter in unterschiedlichen Konzentrationsbereichen direkt ab Lager bereit.
Die QC-Release-Panels werden maßgeschneidert an die benötigten Parameter und Konzentrationsbereiche angepasst:
- Positiv – niedrige, mittlere, hohe Konzentrationen
- Negativ – ohne Analyte, Viren oder spezifische Antikörper
- Cut-off – Werte im Bereich der Nachweisgrenze (LoD) bis hin zum klinischen Entscheidungswert
Besuchen Sie auch unsere Unterseite mit einer umfangreichen Auswahl an humanen Bioproben mit positiven Infektionsmarkern.
Oder nutzen Sie die Gelegenheit, Ihre gewünschten Proben direkt in unserer Datenbank zu suchen:
Besuchen Sie auch unsere Unterseite mit einer umfangreichen Auswahl an humanen Bioproben mit positiven Infektionsmarkern.
Oder nutzen Sie die Gelegenheit, Ihre gewünschten Proben direkt in unserer Datenbank zu suchen:
| Order no. | Product | Panel member | Member volumes | Additional information | |
|---|---|---|---|---|---|
| MSP-HIV-001 | Anti-HIV Mixed subtype panel | 22 | 0.5 mL | Incl. HIV 1, HIV 1 gO, HIV 2 and 2 x neg. | |
| MTP-HTLV-001 | Anti-HTLV I/II mixed titer panel | 15 | 1.0 mL | HTLV I/II pos., neg. and unclear | |
| NP-RUB-001 | Rubella negative panel | 100 | 0.5 mL | |
|
| LPS-HCVAg-001 | HCV Ag linearity panel min | 50 | 1.0 mL | HCV Ag range: 4.0 - 49.941 fmol/L | |
| LPL-HCVAg-001 | HCV Ag linearity panel max | 100 | 1.0 mL | HCV Ag range: 4.0 - 97.243 fmol/L | |
| VAP-HCVAg-001 | HCV Ag validation panel low | 20 | 1.0 mL | HCV Ag range: 4.0 - 1,645.94 fmol/L | |
| VAP-HCVAg-002 | HCV Ag validation panel medium | 20 | 1.0 mL | HCV Ag range: 430 - 18,537 fmol/L | |
| VAP-HCVAg-003 | HCV Ag validation panel high | 20 | 1.0 mL | HCV Ag range: 1,136 - 80,197 fmol/L | |
ZeptoMetrix Panel
The North American company ZeptoMetrix® is one of the market leaders for high quality seroconversion panels with a very favorable price-performance ratio. Seroconversion panels assist diagnostic manufacturers, researchers and clinical laboratories in the development or evaluation of new assays and are therefore an indispensable tool for quality control and quality assurance. The panels contain defined infection markers as well as extensive sample data for comparative analysis.
BIOMEX markets the ZeptoMetrix® product portfolio exclusively in Europe.
| Order no. | Marker | Member | Member volumes | |
|---|---|---|---|---|
| EBV9097 | EBV | 14 | 1.0 mL | |
| HBV10231 | HBV | 16 | 1.0 mL | |
| HBV10232 | HBV | 6 | 1.0 mL | |
| HBV11000 | HBV | 9 | 1.0 mL | |
| HBV11001 | HBV | 8 | 1.0 mL | |
| HBV11002 | HBV | 6 | 1.0 mL | |
| HBV11003 | HBV | 8 | 1.0 mL | |
| HBV11004 | HBV | 8 | 1.0 mL | |
| HBV11005 | HBV | 14 | 1.0 mL | |
| HBV11006 | HBV | 17 | 1.0 mL | |
| HBV11007 | HBV | 14 | 1.0 mL | |
| HBV11008 | HBV | 18 | 1.0 mL | |
| HBV11009 | HBV | 23 | 1.0 mL | |
| HBV11010 | HBV | 18 | 1.0 mL | |
| HBV11011 | HBV | 14 | 1.0 mL | |
| HBV11012 | HBV | 6 | 1.0 mL | |
| HBV11013 | HBV | 35 | 1.0 mL | |
| HBV11014 | HBV | 12 | 1.0 mL | |
| HBV11015 | HBV | 14 | 1.0 mL | |
| HBV11016 | HBV | 10 | 1.0 mL | |
| HBV11017 | HBV | 14 | 1.0 mL | |
| HBV11024 | HBV | 14 | 1.0 mL | |
| HBV11026 | HBV | 16 | 1.0 mL | |
| HBV11027 | HBV | 14 | 1.0 mL | |
| HBV11028 | HBV | 10 | 1.0 mL | |
| HBV11029 | HBV | 13 | 1.0 mL | |
| HBV11031 | HBV | 16 | 1.0 mL | |
| HBV11052 | HBV | 13 | 1.0 mL | |
| HBV11056 | HBV | 11 | 1.0 mL | |
| HBV11058 | HBV | 8 | 1.0 mL | |
| HBV11059 | HBV | 9 | 1.0 mL | |
| HBV11062 | HBV | 12 | 1.0 mL | |
| HBV11064 | HBV | 9 | 1.0 mL | |
| HBV11069 | HBV | 15 | 1.0 mL | |
| HBV6271 | HBV | 5 | 1.0 mL | |
| HBV6272 | HBV | 25 | 1.0 mL | |
| HBV6273 | HBV | 6 | 1.0 mL | |
| HBV6274 | HBV | 7 | 1.0 mL | |
| HBV6275 | HBV | 7 | 1.0 mL | |
| HBV6276 | HBV | 8 | 1.0 mL | |
| HBV6277 | HBV | 11 | 1.0 mL | |
| HBV6278 | HBV | 11 | 1.0 mL | |
| HBV6279 | HBV | 7 | 1.0 mL | |
| HBV6280 | HBV | 5 | 1.0 mL | |
| HBV6281 | HBV | 12 | 1.0 mL | |
| HBV6282 | HBV | 14 | 1.0 mL | |
| HBV6283 | HBV | 11 | 1.0 mL | |
| HBV6284 | HBV | 19 | 1.0 mL | |
| HBV6285 | HBV | 16 | 1.0 mL | |
| HBV6286 | HBV | 9 | 1.0 mL | |
| HBV6287 | HBV | 11 | 1.0 mL | |
| HBV6288 | HBV | 9 | 1.0 mL | |
| HBV6289 | HBV | 10 | 1.0 mL | |
| HBV6290 | HBV | 12 | 1.0 mL | |
| HBV6291 | HBV | 8 | 1.0 mL | |
| HBV6292 | HBV | 12 | 1.0 mL | |
| HBV6293 | HBV | 7 | 1.0 mL | |
| HBV9072 | HBV | 18 | 1.0 mL | |
| HBV9073 | HBV | 16 | 1.0 mL | |
| HBV9074 | HBV | 20 | 1.0 mL | |
| HBV9092 | HBV | 37 | 1.0 mL | |
| HBV9093 | HBV | 31 | 1.0 mL | |
| HBV9098 | HBV | 17 | 1.0 mL | |
| HBV9099 | HBV | 20 | 1.0 mL | |
| HCV10000 | HCV PCR | 10 | 1.0 mL | |
| HCV10002 | HCV PCR | 7 | 1.0 mL | |
| HCV10003 | HCV PCR | 13 | 1.0 mL | |
| HCV10004 | HCV PCR | 6 | 1.0 mL | |
| HCV10007 | HCV PCR | 11 | 1.0 mL | |
| HCV10008 | HCV PCR | 10 | 1.0 mL | |
| HCV10009 | HCV PCR | 6 | 1.0 mL | |
| HCV10010 | HCV PCR | 7 | 1.0 mL | |
| HCV10011 | HCV PCR | 13 | 1.0 mL | |
| HCV10012 | HCV PCR | 13 | 1.0 mL | |
| HCV10013 | HCV PCR | 10 | 1.0 mL | |
| HCV10014 | HCV PCR | 4 | 1.0 mL | |
| HCV10016 | HCV PCR | 12 | 1.0 mL | |
| HCV10017 | HCV PCR | 16 | 1.0 mL | |
| HCV10019 | HCV PCR | 8 | 1.0 mL | |
| HCV10020 | HCV PCR | 13 | 1.0 mL | |
| HCV10021 | HCV PCR | 14 | 1.0 mL | |
| HCV10022 | HCV PCR | 11 | 1.0 mL | |
| HCV10023 | HCV PCR | 21 | 1.0 mL | |
| HCV10024 | HCV PCR | 8 | 1.0 mL | |
| HCV10025 | HCV PCR | 11 | 1.0 mL | |
| HCV10026 | HCV PCR | 12 | 1.0 mL | |
| HCV10027 | HCV PCR | 8 | 1.0 mL | |
| HCV10028 | HCV PCR | 7 | 1.0 mL | |
| HCV10029 | HCV PCR | 16 | 1.0 mL | |
| HCV10030 | HCV PCR | 8 | 1.0 mL | |
| HCV10032 | HCV PCR | 16 | 1.0 mL | |
| HCV10033 | HCV PCR | 10 | 1.0 mL | |
| HCV10036 | HCV PCR | 13 | 1.0 mL | |
| HCV10043 | HCV PCR | 10 | 1.0 mL | |
| HCV10044 | HCV PCR | 4 | 1.0 mL | |
| HCV10045 | HCV PCR | 5 | 1.0 mL | |
| HCV10050 | HCV PCR | 15 | 1.0 mL | |
| HCV10051 | HCV PCR | 14 | 1.0 mL | |
| HCV10052 | HCV PCR | 12 | 1.0 mL | |
| HCV10057 | HCV | 7 | 1.0 mL | |
| HCV10058 | HCV | 7 | 1.0 mL | |
| HCV10062 | HCV | 8 | 1.0 mL | |
| HCV10071 | HCV | 7 | 1.0 mL | |
| HCV10165 | HCV | 9 | 1.0 mL | |
| HCV10185 | HCV | 5 | 1.0 mL | |
| HCV10235 | HCV Pre/Post | 5 | 1.0 mL | |
| HCV6215 | HCV | 4 | 1.0 mL | |
| HCV6216 | HCV | 7 | 1.0 mL | |
| HCV6217 | HCV | 5 | 1.0 mL | |
| HCV6218 | HCV | 8 | 1.0 mL | |
| HCV6219 | HCV | 14 | 1.0 mL | |
| HCV6220 | HCV | 6 | 1.0 mL | |
| HCV6221 | HCV | 8 | 1.0 mL | |
| HCV6222 | HCV | 8 | 1.0 mL | |
| HCV6223 | HCV | 22 | 1.0 mL | |
| HCV6224 | HCV | 6 | 1.0 mL | |
| HCV6225 | HCV | 19 | 1.0 mL | |
| HCV6226 | HCV | 12 | 1.0 mL | |
| HCV6227 | HCV | 7 | 1.0 mL | |
| HCV6228 | HCV | 12 | 1.0 mL | |
| HCV6229 | HCV | 8 | 1.0 mL | |
| HCV9041 | HCV | 8 | 1.0 mL | |
| HCV9042 | HCV | 6 | 1.0 mL | |
| HCV9043 | HCV | 6 | 1.0 mL | |
| HCV9044 | HCV | 6 | 1.0 mL | |
| HCV9045 | HCV | 8 | 1.0 mL | |
| HCV9046 | HCV | 5 | 1.0 mL | |
| HCV9047 | HCV | 10 | 1.0 mL | |
| HCV9048 | HCV | 8 | 1.0 mL | |
| HCV9049 | HCV | 5 | 1.0 mL | |
| HCV9050 | HCV | 13 | 1.0 mL | |
| HCV9054 | HCV | 10 | 1.0 mL | |
| HCV9055 | HCV | 11 | 1.0 mL | |
| HCV9057 | HCV | 11 | 1.0 mL | |
| HCV9058 | HCV | 5 | 1.0 mL | |
| HCV9094 | HCV | 5 | 1.0 mL | |
| HCV9095 | HCV | 5 | 1.0 mL | |
| HIV10234 | HIV Pre/Post | 3 | 1.0 mL | |
| HIV12007 | HIV | 9 | 1.0 mL | |
| HIV12008 | HIV | 13 | 1.0 mL | |
| HIV6244 | HIV | 13 | 1.0 mL | |
| HIV6248 | HIV | 7 | 1.0 mL | |
| HIV9011 | HIV | 11 | 1.0 mL | |
| HIV9012 | HIV | 8 | 1.0 mL | |
| HIV9013 | HIV | 7 | 1.0 mL | |
| HIV9014 | HIV | 5 | 1.0 mL | |
| HIV9015 | HIV | 8 | 1.0 mL | |
| HIV9016 | HIV | 10 | 1.0 mL | |
| HIV9018 | HIV | 11 | 1.0 mL | |
| HIV9019 | HIV | 3 | 1.0 mL | |
| HIV9020 | HIV | 22 | 1.0 mL | |
| HIV9021 | HIV | 17 | 1.0 mL | |
| HIV9022 | HIV | 9 | 1.0 mL | |
| HIV9023 | HIV | 22 | 1.0 mL | |
| HIV9024 | HIV | 12 | 1.0 mL | |
| HIV9025 | HIV | 12 | 1.0 mL | |
| HIV9026 | HIV | 7 | 1.0 mL | |
| HIV9028 | HIV | 7 | 1.0 mL | |
| HIV9029 | HIV | 12 | 1.0 mL | |
| HIV9030 | HIV | 16 | 1.0 mL | |
| HIV9031 | HIV | 19 | 1.0 mL | |
| HIV9032 | HIV | 10 | 1.0 mL | |
| HIV9033 | HIV | 16 | 1.0 mL | |
| HIV9034 | HIV | 13 | 1.0 mL | |
| HIV9075 | HIV | 5 | 1.0 mL | |
| HIV9076 | HIV | 9 | 1.0 mL | |
| HIV9077 | HIV | 27 | 1.0 mL | |
| HIV9078 | HIV | 5 | 1.0 mL | |
| HIV9079 | HIV | 25 | 1.0 mL | |
| HIV9081 | HIV | 4 | 1.0 mL | |
| HIV9082 | HIV | 4 | 1.0 mL | |
| HIV9084 | HIV | 4 | 1.0 mL | |
| HIV9089 | HIV | 6 | 1.0 mL | |
| HIV9096 | HIV | 6 | 1.0 mL | |